Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Net Income towards Common Stockholders: 2019-2025

Historic Net Income towards Common Stockholders for Biodesix (BDSX) over the last 6 years, with Sep 2025 value amounting to -$9.1 million.

  • Biodesix's Net Income towards Common Stockholders rose 14.17% to -$9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$40.0 million, marking a year-over-year increase of 8.24%. This contributed to the annual value of -$42.8 million for FY2024, which is 15.96% up from last year.
  • As of Q3 2025, Biodesix's Net Income towards Common Stockholders stood at -$9.1 million, which was up 21.45% from -$11.6 million recorded in Q2 2025.
  • Biodesix's Net Income towards Common Stockholders' 5-year high stood at -$6.2 million during Q1 2021, with a 5-year trough of -$18.8 million in Q1 2023.
  • Over the past 3 years, Biodesix's median Net Income towards Common Stockholders value was -$10.6 million (recorded in 2024), while the average stood at -$11.4 million.
  • As far as peak fluctuations go, Biodesix's Net Income towards Common Stockholders slumped by 292.35% in 2021, and later surged by 44.05% in 2023.
  • Over the past 5 years, Biodesix's Net Income towards Common Stockholders (Quarterly) stood at -$13.2 million in 2021, then fell by 24.78% to -$16.4 million in 2022, then skyrocketed by 44.05% to -$9.2 million in 2023, then increased by 8.67% to -$8.4 million in 2024, then increased by 14.17% to -$9.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$9.1 million for Q3 2025, versus -$11.6 million for Q2 2025 and -$10.8 million for Q1 2025.